• Vutrisiran Receives EU Approval for hAATR Amyloidosis

    9 days ago - By Medscape

    The RNAi therapeutic vutrisiran has been approved by the European Commission for hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy on the basis of the phase 3 HELIOS-A trial.
    International Approvals
    Read more ...